BRPI0416596A - dispersões amorfas sólidas de um inibidor da mtp para tratamento da obesidade - Google Patents

dispersões amorfas sólidas de um inibidor da mtp para tratamento da obesidade

Info

Publication number
BRPI0416596A
BRPI0416596A BRPI0416596-9A BRPI0416596A BRPI0416596A BR PI0416596 A BRPI0416596 A BR PI0416596A BR PI0416596 A BRPI0416596 A BR PI0416596A BR PI0416596 A BRPI0416596 A BR PI0416596A
Authority
BR
Brazil
Prior art keywords
mtp inhibitor
solid amorphous
obesity treatment
amorphous dispersions
solid
Prior art date
Application number
BRPI0416596-9A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0416596A publication Critical patent/BRPI0416596A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"DISPERSõES AMORFAS SóLIDAS DE UM INIBIDOR DA MTP PARA TRATAMENTO DA OBESIDADE". Uma composição compreende uma dispersão amorfa sólida compreendendo (S)-N-(2-¢benzil(metil)amino!-2-oxo-1-feniletil)-1-metil-5-¢4<39>-(trifluor ometil)-¢1,1<39>-bifenil!-2-carboxamido!-1H-indol-2-carboxamida e um polímero.
BRPI0416596-9A 2003-11-14 2004-11-01 dispersões amorfas sólidas de um inibidor da mtp para tratamento da obesidade BRPI0416596A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51993103P 2003-11-14 2003-11-14
PCT/IB2004/003581 WO2005046644A1 (en) 2003-11-14 2004-11-01 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity

Publications (1)

Publication Number Publication Date
BRPI0416596A true BRPI0416596A (pt) 2007-01-30

Family

ID=34590458

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416596-9A BRPI0416596A (pt) 2003-11-14 2004-11-01 dispersões amorfas sólidas de um inibidor da mtp para tratamento da obesidade

Country Status (16)

Country Link
US (1) US20080293801A1 (pt)
EP (1) EP1696887A1 (pt)
JP (1) JP2007511500A (pt)
KR (1) KR20060096076A (pt)
CN (1) CN1878538A (pt)
AR (1) AR048206A1 (pt)
AU (1) AU2004289110A1 (pt)
BR (1) BRPI0416596A (pt)
CA (1) CA2545443A1 (pt)
CO (1) CO5690536A2 (pt)
IL (1) IL175372A0 (pt)
MX (1) MXPA06005489A (pt)
NO (1) NO20062778L (pt)
NZ (1) NZ546677A (pt)
TW (1) TW200515909A (pt)
WO (1) WO2005046644A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449776T1 (de) * 2005-12-15 2009-12-15 Hoffmann La Roche Pyrroloä2,3-cüpyridinderivate
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
EP2522657B1 (en) * 2010-01-06 2016-08-03 Takeda Pharmaceutical Company Limited Indole derivative
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
EP3861989A1 (en) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4884235A (en) * 1988-07-19 1989-11-28 Thiele Alfred A Micromagnetic memory package
KR0182801B1 (ko) * 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
SK287806B6 (sk) * 2001-06-28 2011-10-04 Pfizer Products Inc. Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B)
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Also Published As

Publication number Publication date
AU2004289110A1 (en) 2005-05-26
NO20062778L (no) 2006-08-14
IL175372A0 (en) 2006-09-05
CO5690536A2 (es) 2006-10-31
TW200515909A (en) 2005-05-16
US20080293801A1 (en) 2008-11-27
NZ546677A (en) 2008-11-28
WO2005046644A1 (en) 2005-05-26
KR20060096076A (ko) 2006-09-05
MXPA06005489A (es) 2006-08-11
CA2545443A1 (en) 2005-05-26
JP2007511500A (ja) 2007-05-10
CN1878538A (zh) 2006-12-13
EP1696887A1 (en) 2006-09-06
AR048206A1 (es) 2006-04-12

Similar Documents

Publication Publication Date Title
BR0307277A (pt) Composições farmacêuticas de inibidores da proteìna de transferencia do éster de colesterilo
NO20075051L (no) Nye sulfonylpyrroler og deres anvendelse som histon-deacetylaseinhibitorer
PT1328269E (pt) Associacao de um antagonista do receptor cb1 e de sibutramina composicoes farmaceuticas que os contem e sua utilizacao para o tratamento da obesidade
TW200606180A (en) Polymer composition
DE60317677D1 (de) Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
EA200802365A1 (ru) Аминометилзамещенные тетрациклиновые соединения
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
EA200300073A1 (ru) Фармацевтические композиции ингибиторов белка переноса холестериловых эфиров
MY136800A (en) Inhibitors of the interaction between mdm2 and p53
BR0317872A (pt) Medicamentos antiinflamatórios
AR045188A1 (es) Procedimientos de secado por pulverizacion para la formacion de dispersiones solidas amorfas de farmacos y polimeros
BRPI0515776A (pt) auxiliares de retenção e drenagem
MX2010001657A (es) Reguladores de mmp-9 y usos de los mismos.
AR038207A1 (es) Composicion farmaceutica dispersable oralmente de agomelatina
ATE516052T1 (de) Zusammensetzungen für knochenzemente enthaltend eine nichtpolymerisierbare organoiodverbindung
TW200637584A (en) External skin agent for preventing inflammation
WO2004024009A8 (en) Bone plates
BRPI0416596A (pt) dispersões amorfas sólidas de um inibidor da mtp para tratamento da obesidade
BR0315554A (pt) Dispersões poliméricas com alta estabilidade e processos para sua preparação
WO2006102220A3 (en) Skin compositions including tensioning polymers and the use thereof
ATE487481T1 (de) N-(4-oxo-3,4-dihydrochinazolin-2-yl)butanamide als androgenrezeptormodulatoren
BRPI0404824A (pt) Processos para preparar uma composição de polìmero, um polìmero multifuncional, e uma composição multifuncional para modificação de cabelos
ATE299703T1 (de) Mmp-hemmer bei bindegewebserweichung
CR9008A (es) Nuevo procedimiento y compuestos intermedios de preparacion de derivados de n-(1-benzhidril-azetidin-3-il)-n-fenilmetilsulfonamida
AU2003264131A1 (en) Polarization-optimized axicon system, and an illuminating system for microlithographic projection system having such an axicon system

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.